Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lu AF95245 is a small molecule drug developed by H. Lundbeck for the treatment of central nervous system disorders. It acts as an agonist of potassium channels, specifically activating the Kv7.2–Kv7.5 (KCNQ2-5) subtypes, which are important in regulating neuronal excitability. The drug was investigated primarily for its potential use in neurological or psychiatric conditions but did not progress beyond early clinical development due to an unfavorable pharmacokinetic profile. Clinical trials included phase 1 studies assessing safety and tolerability in healthy volunteers. Development has since been discontinued.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lu AF95245.